Examine the full equation
Trade-policy uncertainty can intensify interest in North American manufacturing, but labor rates and tariffs provide only part of the business case. Evaluate logistics, inventory, quality, regulatory requirements, supplier exposure, and the cost of disruption alongside direct production expenses.
Plan the transition
Automation can support domestic productivity, while qualified contract manufacturers may offer a faster path than a new facility. Neither option removes execution risk. Validate capacity, expertise, quality systems, and readiness before committing. Reshoring decisions should be tested against the ability to deliver medical technologies reliably to patients and providers, with a transition plan that protects current supply.